Conatus Pharmaceuticals Inc said its experimental drug reduced the presence of a protein fragment in patients with liver cirrhosis in a mid-stage trial. The company’s shares rose 13 percent to $3.25 in after-market trading on Tuesday. The drug, emricasan, showed a statistically significant reduction in the protein fragment, caspase-cleaved cytokeratin 18 (cCK18), when compared with […]